Presenting the results from the PAD subgroup at the European Society of Cardiology (ESC) 2017 Congress, Dr Sonia Anand (McMaster University, Hamilton, ON), said: "Until now we haven't had a ...
ORLANDO, FL—Using the combination of low-dose rivaroxaban (Xarelto; Bayer/Janssen) and aspirin in patients with stable lower-extremity PAD pays dividends not only in preventing major adverse limb ...
A new analysis from the peripheral arterial disease (PAD) subgroup of the large-scale COMPASS trial show that development of a major adverse limb event — the primary endpoint of the study — is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback